Side-by-side · Research reference
CagrilintidevsCortagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BAnimal-MechanisticHUMAN-REVIEWED11/35 cited
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
Injectable · Animal models
01Mechanism of Action
Parameter
Cagrilintide
Cortagen
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
Cerebral cortex tissue — molecular targets under investigation
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Feedback intact?
Yes — acts via physiological amylin pathways
—
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
Cortagen
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Animal mechanistic studies
Animal model dose (rat)
—
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
Avian model dose (chicken)
—
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
Human peripheral nerve study
—
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
Cortagen
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
04Side Effects & Safety
Parameter
Cagrilintide
Cortagen
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Antioxidant suppression
—
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
Immune/hemostasis effects
—
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
Human safety data
—
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Cortagen
—Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
Cortagen
—05Administration Protocol
Parameter
Cagrilintide
Cortagen
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
—
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
Cortagen
— no documented stacks